AU Patent

AU2017201564A1 — Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt

Assigned to Medivation Technologies LLC · Expires 2017-03-23 · 9y expired

What this patent protects

Patent listed against Talzenna.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017201564A1
Jurisdiction
AU
Classification
—
Expires
2017-03-23
Drug substance claim
No
Drug product claim
No
Assignee
Medivation Technologies LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.